Latest research on Erlotinib

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Erlotinib side effects

Forty-one patients experienced improved PS score during Erlotinib treatment because of symptoms relieve. [source, 2016]
The cause-specific HR for Erlotinib versus chemotherapy was 1.695, suggesting an increased risk of 69.5% for chemotherapy than Erlotinib. [source, 2016]
In a phase II clinical trial, Erlotinib (TKI) with Gemcitabine relative to Gemcitabine alone significantly decreased the hazard ratio for death and increased the one year survival rate of pancreatic cancer patients 65. [source, 2016]
This cytokine has recently attracted much interest because EGFR inhibition by Erlotinib was shown to attenuate liver fibrosis and development of HCC in DEN-treated mice and BDL rats (Fuchs et al., 2014). [source, 2016]
In terms of single SNPs analysis, we first identified a strong association between an SNP rs884225 C > T in 3′UTR of EGFR and increased risk of ADR to Erlotinib. [source, 2016]
Erlotinib treatment, at a concentration of 5 μM, decreased cell viability of hMSC-TERT4 to 0.65 (95% CI: 0.63–0.68) and that of hMSC-TERT20-CE8 to 0.88 (95% CI: 0.783–0.96). [source, 2016]
The results of our experiments are in agreement with the clinical results since they showed that the EGFR activated signaling in nontransformed and transformed stromal cell lines did not result in increased sensitivity to treatment with the EGFR inhibitors Erlotinib and afatinib. [source, 2016]
Because objective tumor responses are not expected with the use of biologic agents in HCC, the combination of bevacizumab plus Erlotinib was considered potentially active, if the 16-week PFS rate was similar to that of historic controls.13 [source, 2016]
After initial adaptation, the Erlotinib concentration was gradually increased to 4 μM. [source, 2016]
The increased migration, Erlotinib resistance, and reduced proliferation of HCC4006ER cells were consistent with an EMT process. [source, 2016]